Advantages of using reduced-volume intensity modulated radiation therapy for the treatment of nasopharyngeal carcinoma: a retrospective paired study

Table 6 Effects of subgroups on late toxicity in nasopharyngeal carcinoma underwent CV-IMRT versus RV-IMRT

Variate		P value
Variate		Xerostomia	Mucositis	Skin reaction	Dysphagia	Hearing loss	Blurred vision
Sex	Female	0.511	0.562	0.362	0.36	0.077	0.625
Sex	Male	0.038	0.145	0.893	0.716	0.042	0.532
Age	< 45	0.483	0.831	0.613	0.32	0.023	0.327
Age	≥45	0.036	0.384	0.215	0.838	0.12	0.756
T stage	T1–2	0.008	0.348	0.987	0.97	0.01	0.06
T stage	T3–4	0.995	0.717	0.542	0.252	0.253	0.272
N stage	N0–1	0.255	0.546	0.676	0.787	0.01	0.969
N stage	N2–3	0.079	0.553	0.81	0.236	0.185	0.252
Clinical stage	I-II	0.269	0.373	0.78	1	0.011	0.607
Clinical stage	III-IV	0.087	0.635	0.765	0.353	0.099	0.779
Neoadjuvant/adjuvant chemotherapy	No	0.715	0.897	0.363	0.675	0.017	1
Neoadjuvant/adjuvant chemotherapy	Yes	0.036	0.406	0.86	0.318	0.049	0.585
Concurrent chemotherapy	No	0.419	0.605	0.402	0.696	0.003	–
Concurrent chemotherapy	Yes	0.053	0.492	0.831	0.318	0.069	0.412

CV-IMRT conventional-volume intensity-modulated radiation therapy, RV-IMRT reduced-volume intensity-modulated radiation therapy

ISSN: 1471-2407